Company Overview
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -79.63% |
| 6 Months: | -80.41% |
| 3 Months: | -48.29% |
| 1 Month: | -4.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTL Artelo Biosciences, Inc. PHARMA | 6.19 | -0.06 | $3.39M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Feb 2014 | May 2014 | Nov 2014 | Feb 2015 | May 2015 | Nov 2015 | Feb 2016 | May 2016 | Nov 2016 | Feb 2017 | May 2017 | Nov 2017 | Feb 2018 | May 2018 | Nov 2018 | Feb 2019 | May 2019 | Nov 2019 | Feb 2020 | May 2020 | Nov 2020 | Feb 2021 | Mar 2021 | May 2021 | Jun 2021 | Sep 2021 | Nov 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -6.59K | -8.15K | -2.00K | -6.15K | -2.50K | -15.22K | -5.09K | -5.05K | -9.52K | -11.99K | -95.72K | -277.06K | -798.46K | -577.86K | -556.90K | -757.92K | -941.29K | -1.34M | -1.37M | -951.39K | -1.44M | -1.87M | -1.70M | -2.25M | -2.25M | -2.25M | -2.55M | -1.95M | -2.47M | -2.39M | -2.29M | -1.78M | -2.61M | -2.59M | -2.51M | -1.20M | -2.38M | -3.15M | -3.09M | -2.69M |
| Net Income | -6.59K | -8.15K | -2.00K | -6.15K | -2.50K | -15.22K | -5.09K | -5.05K | -9.52K | -13.01K | -96.63K | -277.06K | -798.46K | -577.86K | -556.90K | -424.79K | -344.88K | -1.31M | -1.37M | -951.19K | -1.44M | -1.87M | -1.70M | -2.25M | -2.25M | -2.25M | -2.55M | -1.97M | -2.45M | -2.33M | -2.17M | -1.60M | -2.45M | -2.48M | -2.43M | -1.13M | -2.37M | -3.22M | -3.12M | -2.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.07 | -0.36 | -0.32 | -0.40 | -0.40 | -0.40 | -0.40 | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.83 | -0.78 | -4.52 | -2.10 | -12.55 | -5.61 | -3.97 | -4.00 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 33.08K | 647.47K | 236.84K | 184.04K | 489.98K | 184.20K | 666.94K | 721.31K | 258.68K | 595.00K | 663.36K | 307.00K | 951.20K | 970.00K | 1.03M | 1.27M | 464.00K | 1.06M | 1.08M | 1.24M | 752.00K | 1.58M | 1.51M | 1.69M | 325.00K | 1.38M | 1.87M | 1.27M | 773.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -15.27K | -15.24K | -29.69K | -232.79K | -2.34M | -3.21M | -4.69M | -7.44M | -9.42M | -10.29M | -9.93M | -10.11M | -11.40M |
| Net Income | -15.27K | -15.24K | -29.69K | -234.89K | -2.34M | -2.17M | -4.66M | -7.44M | -9.41M | -10.08M | -9.29M | -9.83M | -12.88M |
| Diluted EPS | - | - | - | - | -1.84 | -1.46 | - | - | - | - | -3.14 | -18.30 | -12.52 |
| R&D Expense | - | - | - | - | 1.25M | 1.09M | 1.92M | 2.84M | 3.78M | 4.32M | 5.70M | 5.99M | 5.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 14.73K | 17.03K | 3.59K | 574.27K | 397.00K | 6.48M | 4.38M | 12.63M | 28.25M | 20.42M | 13.04M | 4.70M | 2.80M |
| Total Equity | 14.73K | 15.89K | -13.80K | 544.84K | -134.97K | 5.46M | 3.88M | 12.04M | 27.17M | 19.40M | 11.75M | 2.86M | -1.27M |
| Cash & Equivalents | 14.73K | 17.03K | 3.59K | 572.77K | 337.42K | 4.42M | 2.14M | 6.63M | 12.16M | 6.89M | - | - | 600.00K |
| Total Liabilities | - | 1.74K | 17.39K | - | - | - | 501.00K | 593.00K | 1.08M | 1.02M | 1.29M | 1.84M | 4.07M |
| Current Liabilities | - | 1.74K | 17.39K | 29.44K | 531.97K | 1.02M | 501.00K | 526.00K | 1.03M | 998.00K | 1.29M | 1.77M | 4.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -216.82K | -1.61M | -2.79M | -4.35M | -6.14M | -8.01M | -8.21M | -8.35M | -8.52M |
| Investing Cash Flow | - | -845 | -1.50M | 0 | -3.44M | 2.96M | 3.51M | 7.77M | -62.00K |
| Financing Cash Flow | 785.35K | 1.39M | 8.38M | 1.98M | 14.11M | 0 | 567.00K | 112.00K | 6.87M |
Ratios (Annual)
Figures in %.
| Metric | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -103.7% | -95.9% | 215.1% | -43.1% | 1,736.3% | -39.8% | -120.1% | -61.8% | -34.6% | -52.0% | -79.0% | -343.9% | 1,012.5% |
| ROCE % | - | -99.7% | 215.1% | -42.7% | 1,736.3% | -58.8% | -120.9% | -61.5% | -34.6% | -53.0% | -84.5% | -345.5% | 917.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 1.35% | 7.37K | $29.04K |
| 2 | Geode Capital Management, LLC | 0.28% | 1.54K | $6.07K |
| 3 | Stonex Group Inc. | 0.25% | 1.38K | $5.43K |
| 4 | Vanguard Capital Management LLC | 0.21% | 1.12K | $4.43K |
| 5 | Tower Research Capital LLC (TRC) | 0.17% | 937 | $3.69K |
| 6 | Vanguard Fiduciary Trust Co | 0.06% | 349 | $1.38K |
| 7 | UBS Group AG | 0.06% | 312 | $1.23K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARTL
A pharmaceutical CEO will speak in New York as Artelo joins a Sept. 14-16 conference. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQdUszTHRJbEpScUlIWEQyUmFwOWp5dnJTOGhlZVI2Y1BVU05jOXUxMTRDWGJ4OE9jTmJucmp3TmQ4UTJqMy0xald3M0VfN05jdmVybC1oWVlBbjdOeXZqXy1PaHQ0ZWI1WkJPY1BFQ3BkUE5wS3Jla0NzVlpTTlUzSUpDLVNFRm9yLThQaH…
Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1wZGZCWTFDOU1CSWlXODF6WTZZd2cwb1I0SVRKa3Jrck4wUVBFRXk4akJ2N2RuV2RYWnNzSXRyRmw4NVhENlQzWQ?oc=5" target="_blank">Artelo Biosciences Stock Price Forecast. Should You Buy ARTL?</a>&nbs…
Price-Driven Insight from (ARTL) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNeEJndi0teERNenBvQjM2akFYdXFYbWlFNU4wRlF2MFBlcWQwMk1ZS3kweUdjT29KSGFrOUJ2Rk1iQzcyRXFZZTBHMGtTeVNET3pSZl9ETUstakZKVGZFNm5PYS1nYzBtWnc3dWJvd2JaVndnVmlPQnVING10ZlNSOXlxa0xFSmtlM1hNM2…
Artelo Biosciences Announces Reverse Stock Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOY2R3WVl5N18tU2dRVjJfMVJiRkJoc3VCVEZ5bXRCOV9BdVFKRFZQeVVrUmVVVmhvcC1FN2dzUk4wM1NNR2FKLWRYeWppeXhnZUtRQnAxR2xfREQzTmxYR2lPTTdjdGs1T1VHd3lyOXQ4ZmxPd0pSSlNZS0h4emFGdUhrS1o3WWpDT1A3dW…
Why Is ARTL Stock Soaring Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNLXFlRHNtWnBjTkRTZUNJRHdrUUhQb2ZRSkdTOUlxbmltZHQwSE81WG5iV2duM0NlaFE2TzRWZXFwek9ob1N4dWV6SEhJdXVDWUtoRG9yR193OGlRUDMtU211QmF4QnpFZUFHYkZodHlndG4zQ2pNcjlpN3Q4VzBPdy1seVpMLU8tNG1ETn…
Artelo Biosciences jumps after Nasdaq compliance update, with low-float volatility likely adding fuel | ARTL Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPaGhTWUlSM0dHTXBwLV9jQmNOdld5c29xQkhrX3hoTnpnaE10WUVNUlNPTko2ZnJia2NZc0JOTE5DMHdmbHZWNmJoRHNFZjE4d2I3QThnWU12WGUtMFUwVU5ScFNBeEdJaURKLU5kM1FRa0I5cXdXZnNBYV9Oci1xbkk2azE0N2VVYmo2cW…
ARTL — Frequently Asked Questions
What is the current share price of Artelo Biosciences, Inc. (ARTL)?
As of 2026-09-19 21:16 PDT, Artelo Biosciences, Inc. (ARTL) trades at $6.19 on NasdaqCM. Its 52-week range is $5.95 to $159.03.
What is the market capitalisation of ARTL?
Artelo Biosciences, Inc. (ARTL) has a market capitalisation of $3.39M on NasdaqCM.
What is the P/E ratio of ARTL?
ARTL trades at a trailing price-to-earnings (P/E) ratio of -0.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.56.
Is ARTL a good stock to buy?
This page provides a data-driven analysis of Artelo Biosciences, Inc. (ARTL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.